172 related articles for article (PubMed ID: 26042424)
1. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
2. DC-SIGN ligation greatly affects dendritic cell differentiation from monocytes compromising their normal function.
Svajger U; Obermajer N; Anderluh M; Kos J; Jeras M
J Leukoc Biol; 2011 Jun; 89(6):893-905. PubMed ID: 21447648
[TBL] [Abstract][Full Text] [Related]
3. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
5. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
7. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
8. p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells.
Che KF; Shankar EM; Muthu S; Zandi S; Sigvardsson M; Hinkula J; Messmer D; Larsson M
Mol Med; 2012 Oct; 18(1):1169-82. PubMed ID: 22777388
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W
Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
11. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human dendritic cells and enhances T cell activation.
Messmer D; Hatsukari I; Hitosugi N; Schmidt-Wolf IG; Singhal PC
Mol Med; 2006; 12(11-12):284-90. PubMed ID: 17380193
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.
Takahashi A; Kono K; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Immunol Immunother; 2004 Jun; 53(6):543-50. PubMed ID: 14666382
[TBL] [Abstract][Full Text] [Related]
13. C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulation.
Teh BK; Yeo JG; Chern LM; Lu J
Mol Immunol; 2011 May; 48(9-10):1128-38. PubMed ID: 21429584
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation.
Bharadwaj U; Zhang R; Yang H; Li M; Doan LX; Chen C; Yao Q
J Surg Res; 2005 Jul; 127(1):29-38. PubMed ID: 15964302
[TBL] [Abstract][Full Text] [Related]
15. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Kernt M; Thiele S; Liegl RG; Kernt B; Eibl K; Haritoglou C; Ulbig MW; Kampik A
Growth Factors; 2012 Feb; 30(1):49-61. PubMed ID: 22168366
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
17. Metallic haptens induce differential phenotype of human dendritic cells through activation of mitogen-activated protein kinase and NF-kappaB pathways.
Antonios D; Ade N; Kerdine-Römer S; Assaf-Vandecasteele H; Larangé A; Azouri H; Pallardy M
Toxicol In Vitro; 2009 Mar; 23(2):227-34. PubMed ID: 19101624
[TBL] [Abstract][Full Text] [Related]
18. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats.
Zhu XM; Yao YM; Liang HP; Xu S; Dong N; Yu Y; Sheng ZY
J Interferon Cytokine Res; 2009 Oct; 29(10):677-86. PubMed ID: 19642897
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
[TBL] [Abstract][Full Text] [Related]
20. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
